Small molecule inhibitors reveal PTK6 kinase is not an oncogenic driver in breast cancers

Luping Qiu; Kymberly Levine; Ketan S. Gajiwala; Ciarán N. Cronin; Asako Nagata; Eric Johnson; Michelle Kraus; John Tatlock; Robert Kania; Timothy Foley; Shaoxian Sun

doi:10.1371/journal.pone.0198374

Loading metrics

Open Access

Peer-reviewed

Research Article

Small molecule inhibitors reveal PTK6 kinase is not an oncogenic driver in breast cancers

Luping Qiu ,

Contributed equally to this work with: Luping Qiu, Kymberly Levine

Roles Data curation, Formal analysis, Methodology, Writing – original draft

Affiliation Center of Therapeutic Innovation, Pfizer Inc., New York, NY, United States of America
⨯
Kymberly Levine ,

Contributed equally to this work with: Luping Qiu, Kymberly Levine

Roles Data curation, Formal analysis, Methodology, Writing – original draft

Affiliation Center of Therapeutic Innovation, Pfizer Inc., New York, NY, United States of America
⨯
Ketan S. Gajiwala,

Roles Data curation, Formal analysis, Writing – original draft, Writing – review & editing

Affiliation Worldwide Medicinal Chemistry, Pfizer Inc., San Diego, CA, United States of America
⨯
Ciarán N. Cronin,

Roles Data curation, Formal analysis, Methodology, Writing – original draft, Writing – review & editing

Affiliation Worldwide Medicinal Chemistry, Pfizer Inc., San Diego, CA, United States of America
⨯
Asako Nagata,

Roles Data curation, Formal analysis, Methodology

Affiliation Worldwide Medicinal Chemistry, Pfizer Inc., San Diego, CA, United States of America
⨯
Eric Johnson,

Roles Methodology

Affiliation Worldwide Medicinal Chemistry, Pfizer Inc., San Diego, CA, United States of America
⨯
Michelle Kraus,

Roles Methodology

Affiliation Worldwide Medicinal Chemistry, Pfizer Inc., San Diego, CA, United States of America
⨯
John Tatlock,

Roles Formal analysis, Investigation

Affiliation Worldwide Medicinal Chemistry, Pfizer Inc., San Diego, CA, United States of America
⨯
Robert Kania,

Roles Resources

Affiliation Worldwide Medicinal Chemistry, Pfizer Inc., San Diego, CA, United States of America
⨯
Timothy Foley,

Roles Resources

Affiliation Primary Pharmacology, Pfizer Inc., Groton, CT, United States of America
⨯
Shaoxian Sun

Roles Conceptualization, Data curation, Formal analysis, Supervision, Writing – original draft, Writing – review & editing

* E-mail: shaoxian@yahoo.com

Current address: Regeneron Pharmaceuticals Inc., Tarrytown, NY, United States of America

Affiliation Center of Therapeutic Innovation, Pfizer Inc., New York, NY, United States of America

http://orcid.org/0000-0003-4751-3025

⨯

Small molecule inhibitors reveal PTK6 kinase is not an oncogenic driver in breast cancers

Luping Qiu,
Kymberly Levine,
Ketan S. Gajiwala,
Ciarán N. Cronin,
Asako Nagata,
Eric Johnson,
Michelle Kraus,
John Tatlock,
Robert Kania,
Timothy Foley

Published: June 7, 2018
https://doi.org/10.1371/journal.pone.0198374

Reader Comments (0)

Post a new comment on this article

Subject Areas
?

For more information about PLOS Subject Areas, click here.
We want your feedback. Do these Subject Areas make sense for this article? Click the target next to the incorrect Subject Area and let us know. Thanks for your help!

Breast cancer
Is the Subject Area "Breast cancer" applicable to this article?

Thanks for your feedback.
Cancer treatment
Is the Subject Area "Cancer treatment" applicable to this article?

Thanks for your feedback.
Crystal structure
Is the Subject Area "Crystal structure" applicable to this article?

Thanks for your feedback.
Kinase inhibitors
Is the Subject Area "Kinase inhibitors" applicable to this article?

Thanks for your feedback.
Carcinogenesis
Is the Subject Area "Carcinogenesis" applicable to this article?

Thanks for your feedback.
Crystallization
Is the Subject Area "Crystallization" applicable to this article?

Thanks for your feedback.
Breast tumors
Is the Subject Area "Breast tumors" applicable to this article?

Thanks for your feedback.
Cell membranes
Is the Subject Area "Cell membranes" applicable to this article?

Thanks for your feedback.